Covington & Burling LLP operates as a limited liability partnership worldwide, with the practice in England and Wales conducted by an affiliated limited liability multinational partnership, Covington & Burling LLP, which is formed under the laws of the State of Delaware in the United States and authorized and regulated by the Solicitors Regulation Authority with registration number 77071..
The Consolidated Appropriations Act, 2023 contains various policy riders that reshape FDA's drug and device authorities. During this webinar, experts from PhRMA and Covington's Food, Drug and Device practice group will discuss these reforms, including new and amended laws on clinical trial diversity, accelerated approval, and drug/device classification.
To read more on this legislation, please click here for our recent alert on this matter.
We will discuss key implications for industry stakeholders, cover the policies that did not make it into the year-end legislation, and discuss what that means for FDA and potential future legislation.
Thursday, January 19, 2023
12 - 1 p.m. ET
9 - 10 a.m. PT
Click here to register. Log-in details provided upon registration.
Presenters
Krista Carver, Covington
kcarver@cov.com
Scott Danzis, Covington
sdanzis@cov.com
Wade Ackerman, Covington
ackermanw@cov.com
Kelly Goldberg, PhRMA